TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02293291

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Water
Description: To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lithium Water
Description: To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI
Study: NCT02217631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 BS H3PO4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone low dose
Study: NCT03747744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD1c (BDCA-1)+ myDC
Description: Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
Study: NCT01701219

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline fosamil
Description: Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
Study: NCT02217631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00653484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Energy Restriction
Study: NCT02196740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste
Description: Pulp removal,Root canal irrigation and disinfection,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: creosote
Description: Pulp removal,Root canal irrigation and disinfection
Study: NCT01277718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
Study: NCT05173246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg, ivdrip, d1, Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2, ivdrip,d1,Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5,d1,Q3w
Study: NCT01758055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MSCs transplantation
Description: Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
Study: NCT03646357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-betablocker
Description: No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betablocker
Description: A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.
Study: NCT00373373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 2 x 400 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chemotherapy + Placebo
Study: NCT02359565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo standard MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging
Description: Undergo DTI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo MR diffusion imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-enhanced MR Perfusion
Description: Undergo DCE permeability MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging
Description: Undergo DSC perfusion MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03721822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Study: NCT03110965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga poses
Description: Patients are asked to perform one or two yoga poses daily for 4-10 months
Study: NCT03279861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: First line therapy in Entresto arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: First line therapy in Entresto arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: First line therapy in usual meds arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: First line therapy in usual meds arm
Study: NCT00933426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
Study: NCT04446598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative SMOOTH mode Erbium YAG laser
Description: Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: oral tadalafil 5 mg was administered daily over a period of two months
Study: NCT01582646

Intervention type: DRUG
Group type: OTHER
Intervention: Terbutaline sustained release 5 mg
Description: Terbutaline 10mg oral per day (5 mg twice a day) during 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Terbutaline sustained release 5 mg
Description: Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
Study: NCT02881203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Well
Description: Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPM
Description: Varian Real-time Position Management (RPM) system
Study: NCT03190226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Description: split-mouth design, randomized L-PRF membranes vs. free gingival graft
Study: NCT02881203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RPM
Description: Varian Real-time Position Management (RPM) system
Study: NCT03190226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: split-mouth design, randomized L-PRF membranes vs. free gingival graft
Study: NCT02299141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study: NCT00380276

Intervention type: DRUG
Group type: OTHER
Intervention: MPC-7869
Description: 800 mg BID Oral dosing
Study: NCT00765128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study: NCT01827345

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
Study: NCT03653052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
Study: NCT01598519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suicide intervention
Description: universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net.
Study: NCT02543437

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident Acetabular X3 Insert
Study: NCT00059787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Given PO
Study: NCT00472797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation Non Titrated
Description: human interferon beta 1a - Rebif New Formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation Titrated
Description: Human interferon beta 1a Rebif New Formulation
Study: NCT04300829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cicaderma + simple hygiene rules
Description: Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple hygiene rules and a maximum of one topical treatment
Description: Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
Study: NCT02547402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: It is statin medicine used to lower cholesterol and triglycerides in the blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin® (combination of simvastatin and ezetimibe)
Description: It lowers bad cholesterol in the blood, and raises good cholesterol
Study: NCT03165955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
Study: NCT01805726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xylocain
Description: Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: (A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
Study: NCT00174382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
Study: NCT04050969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation (AF) Catheter Ablation
Description: Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) Catheter Ablation
Description: Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
Study: NCT06716723

Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: Receipt of a laparoscopic nephrectomy for kidney donation
Study: NCT03470870

Intervention type: OTHER
Intervention: Comparative analysis of the characteristics
Description: * Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program

Intervention type: OTHER
Intervention: Comparative analysis of the characteristics
Description: * Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program
Study: NCT02059382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ChiRunning training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChiRunning training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: unblinded accelerometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: participation in online social network

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: participation in study website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology support for behavior change
Study: NCT01736514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: oral
Study: NCT01493778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
Study: NCT02102841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin suction blister

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin suction blister

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Study: NCT01611246

Intervention type: DEVICE
Intervention: Iontophoresis System With Earset
Description: iontophoresis of lidocaine-based solution for numbing tympanic membrane
Study: NCT02538107

Intervention type: DRUG
Intervention: Methoxy-polyethyleneglycol epoetin beta
Study: NCT00546754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Valsartan (+) Hydrochlorothiazide
Description: Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
Study: NCT00125645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan Oral Tablet
Study: NCT01993160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorocholine (18F-FCH) Injection
Description: Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole body MRI
Description: A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
Study: NCT01912131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single pilot interview
Description: Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals-of-care (GOC) video
Description: Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals-of-care (GOC) video and narrative question
Description: subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Subjects in the usual care arm will neither be given the narrative stem nor watch the video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part 2
Description: Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2
Description: Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part 2
Description: Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
Study: NCT05600335

Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy

Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
Study: NCT00895531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depodur
Description: 7.5 mg Depodur via the epidural catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.